Regulus Therapeutics is a cutting-edge brand that is dedicated to delivering life-changing therapeutics to patients suffering from orphan kidney diseases. With a laser-like focus on improving the lives of patients and their families, the brand is committed to developing innovative solutions for kidney diseases with high unmet needs, including autosomal dominant polycystic kidney disease (ADPKD). Regulus Therapeutics' pipeline programs aim to target the underlying biology of these diseases through the use of MicroRNA-based therapeutics.

This novel approach has the potential to revolutionize the treatment landscape for kidney diseases. The brand has made significant advancements in its mission, with recent milestones including the announcement of the first patient dosed in the second cohort of a Phase 1b Multiple-Ascending Dose (MAD) clinical trial for the treatment of ADPKD. Regulus Therapeutics continues to be at the forefront of innovation, with a commitment to rigorous clinical trials and cutting-edge technology.

With a strong focus on patient-centric care, the brand is dedicated to transforming the lives of individuals affected by kidney diseases. Copyright 2023 Regulus Therapeutics – All rights reserved. Terms and Conditions apply